Tumour cell heterogeneity affects cisplatin but not doxorubicin cytotoxicity in two phenotypes of the triple-negative breast cancer (TNBC) cell line, MDA-MB-231. A mesenchymal MDA-MB-231 phenotype was three times less sensitive to cisplatin than an epithelial-type phenotype from the same cell line, which has important implications in the success of TNBC chemotherapies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jinorgbio.2022.112082 | DOI Listing |
Publication Analysis
Top Keywords
tumour cell
8
cell heterogeneity
8
triple-negative breast
8
breast cancer
8
cisplatin doxorubicin
8
heterogeneity triple-negative
4
cancer cells
4
cells response
4
response cisplatin
4
doxorubicin tumour
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!